Non-absorbable antibiotics for managing intestinal gas production and gas-related symptoms

Alimentary Pharmacology and Therapeutics

Volumn 14, Issue 8, 2000, Pages 1001-1008

  Di Stefano, M ^a   Strocchi, A ^a   Malservisi, S ^a   Veneto, G ^a   Ferrieri, A ^a   Corazza, G R ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED CARBON; HYDROGEN; LACTULOSE; METHANE; RIFAXIMIN; TUBERCULOSTATIC AGENT;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FLATULENCE; GAS; GASTROINTESTINAL SYMPTOM; HUMAN; HYDROGEN BREATH TEST; MALE; PRIORITY JOURNAL;

ABSORPTION; ADULT; AGED; CHARCOAL; DOUBLE-BLIND METHOD; FEMALE; FLATULENCE; GASTROINTESTINAL AGENTS; HUMANS; HYDROGEN; MALE; MIDDLE AGED; RIFAMYCINS; TREATMENT OUTCOME;

EID: 0033854244     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2000.00808.x     Document Type: Article

References (31)

1. 1 Strocchi A, Levitt MD. Intestinal gas. In: Sleisenger MH, Fordtran JS, eds. Gastrointestinal Disease. Philadelphia: Saunders, 1993: 1035-42.
2. 2 Levitt MD, Bond JH. Volume, composition and source of intestinal gas. Gastroenterology 1970; 59: 921-9.
3. 3 King TS, Elia M, Hunter JO. Abnormal colonic fermentation in irritable bowel syndrome. Lancet 1998; 352: 1187-9.
4. 4 Levitt MD, Lasser RB, Schwartz JS, Bond JH. Studies of a flatulent patient. N Engl J Med 1976; 295: 260-2.
5. 5 Hall RG Jr, Thompson H, Strother A. Effects of orally administered activated charcoal on intestinal gas. Am J Gastroenterology 1981; 75: 192-6.
6. 6 Jain NK, Patel VP, Pitchumoni CS. Activated charcoal, simethicone, and intestinal gas: a double-blind study. Ann Intern Med 1986; 105: 61-2.
7. 7 Potter T, Ellis C, Levitt MD. Activated charcoal: in vivo and in vitro studies of effect on gas formation. Gastroenterology 1985; 88: 620-4.
8. 8 White JG, Hightower NC, Riggs M, Dyck WP. Does activated charcoal relieve gas symptoms? - a placebo controlled study. Gastroenterology 1991; 100: A261 (Abstract).
9. 2 production and gastrointestinal symptoms. Digestion 1991; 49: 227-30.
10. 10 Bjorneklett A, Midtvedt T. Influence of three antimicrobial agents-penicillin, metronidazole and doxycyclin - on the intestinal microflora of healthy humans. Scand J Gastroenterol 1981; 16: 473-80.
11. 11 Rao SC, Edwards CA, Austen CJ, Bruce C, Read NW. Impaired colonic fermentation of carbohydrate after ampicillin. Gastroenterology 1988; 94: 928-32.
12. 12 Caspary WF, Lembcke B, Elsehans B. Bacterial fermentation of carbohydrates within the gastrointestinal tract. Clin Res Rev 1981; 1 (Suppl. 1): 107-17.
13. 13 Marchi E, Mascellani G, Montecchi L, Brufani M, Cellai L. L/105, a new semisynthetic derivative of Rifamycin sv, synthesis and structure-activity relationship. Chemioterapia 1983; 2: 48-50.
14. 14 Lamanna A, Orsi A. In vitro activity of Rifaximin and Rifamycin against some anaerobic bacteria. Chemioterapia 1984; 6: 365-7.
15. 15 Papi C, Ciaco A, Koch M, Capurso L. Efficacy of rifaximin on symptomatic diverticular disease of the colon. A multicentre double-blind placebo-controlled trial. Aliment Pharmacol Ther 1995; 9: 33-9.
16. 16 Corazza GR, Ventrucci M, Strocchi A, et al. Treatment of small intestine bacterial overgrowth with rifaximin a non-absorbable rifamycin. J Internat Med Res 1988; 16: 312-6.
17. 17 Di Stefano M, Malservisi S, Veneto G, Ferrieri A, Corazza GR. Rifaximin versus chlortetracycline in the short-term treatment of small intestine bacterial overgrowth. Aliment Pharmacol Ther 2000; 14: 551-556.
18. 18 Thompson WG, Dotevall G, Drossman DA, Heaton KW, Kruis W. Irritable bowel syndrome: guidelines for the diagnosis. Gastroenterol Internat 1989; 2: 92-5.
19. 19 Huskinsson EC. Measurement of pain. Lancet 1974; 2: 1127-31.
20. 20 Maxton DG, Martin DF, Whorwell PJ, Godfrey M. Abdominal distention in female patients with irritable bowel syndrome: exploration of possible mechanisms. Gut 1991; 32: 662-4.
21. 21 Corazza GR, Strocchi A, Gasbarrini G. Fasting breath hydrogen in celiac disease. Gastroenterology 1987; 93: 53-8.
22. 22 Thompson DG, O'Brien JD, Hardie JM. Influence of the oropharyngeal microflora on the measurements of exhaled breath hydrogen. Gastroenterology 1986; 91: 853-60.
23. 23 Rosenthal A, Solomons NW. Time-course of cigarette smoke contamination of clinical hydrogen breath-analysis tests. Clin Chem 1983; 29: 1980-1.
24. 2) response to carbohydrate malabsorption after exercise. J Lab Clin Med 1983; 102: 147-50.
25. 25 Kotler DP, Holt PR, Rosensweig NS. Modification of the breath hydrogen test: increased sensitivity for the detection of carbohydrate malabsorption. J Lab Clin Med 1982; 100: 789-805.
26. 26 Corazza GR, Benati G, Strocchi A, Malservisi S, Gasbarrini G. The possible role of breath methane measurement in detecting carbohydrate malabsorption. J Lab Clin Med 1994; 124: 695-700.
27. 27 Strocchi A, Levitt MD. Factors affecting hydrogen production and consumption by human fecal flora. The critical role of hydrogen tension and methanogenesis. J Clin Invest 1992; 89: 1304-11.
28. 28 Lasser RB, Bond JH, Levitt MD. The role of intestinal gas in functional abdominal pain. N Engl J Med 1975; 293: 524-6.
29. 29 Chami TN, Schuster MM, Bohlman ME, Pulliam TJ, Kamal N, Whitehead WE. A simple radiologic method to estimate the quantity of bowel gas. Am J Gastroenterol 1991; 86: 599-602.
30. 2 criteria. Gastroenterology 1993; 105: 1404-10.
31. 31 Levitt MD, Furne J, Olsson S. The relation of passage of gas and abdominal bloating to colonic gas production. Ann Intern Med 1996; 124: 422-4.